This provider's $15.4M in total Medicare payments ranks in the 94th percentile of Clinical Laboratory providers nationally.
Medicare payments to this provider grew 1779% from 2022 to 2023.
95% of their billing comes from a single procedure code (K1034 — Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count).
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 1779% in 2023
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2022 | $11.28 | $2.76 | 4.09x | $8.52 | $777.2K | 281.8K | 6 |
| 2023 | $14.06 | $11.05 | 1.27x | $3.01 | $14.6M | 1.3M | 1 |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1.3M | $14.6M | $11.05 | 1.27x |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 268.9K | $277.1K | $1.03 | 4.85x |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 3.2K | $235.2K | $74.32 | 4.04x |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | 3.2K | $110.8K | $35.01 | 4.28x |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within | 3.1K | $78.0K | $24.77 | 3.03x |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3.1K | $73.2K | $23.25 | 2.15x |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 248 | $2.6K | $10.31 | 5.47x |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | 11 | $278.31 | $25.30 | 1.98x |
This provider submits charges 1.41 times higher than what Medicare actually pays.
A markup ratio of 1.41x means for every $100 Medicare pays, this provider initially charges $141. This is lower than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Clinical Laboratory providers in IL for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Quest Diagnostics Llc Il | Wood Dale, IL | $446.2M | ⚠️ Flagged |
| Tempus Ai, Inc. | Chicago, IL | $213.4M | ⚠️ Flagged |
| Chicago Clinical Laboratories, Ltd | Northbrook, IL | $66.5M | ⚠️ Flagged |
| Lifescan Labs Of Illinois, Llc | Skokie, IL | $61.6M | ✓ Clear |
| Chicago Care Lab Services Llc | Chicago, IL | $56.7M | ⚠️ Flagged |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data